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Abstract
Background: VLA-4 and CD38 predict a poor clinical outcome in chronic lymphocytic leukemia (CLL). We used CLL samples
with discordant VLA-4/CD38 risk to address their individual roles in human bone marrow infiltration (BM), CLL cell homing
to murine BM, and in supportive CLL cell-stromal cell interactions.
Methods: VLA-4, CD38, and Ki-67 expression was measured in CLL cells from peripheral blood (PB) and bone marrow (BM)
aspirates. CLL BM infiltration rates, routinely determined by Pathology, were correlated to VLA-4 and CD38 expression.
Short-term homing capacity of CLL cells was evaluated by adoptive transfer experiments. CLL cell viability and adhesion in
stromal cell co-culture was determined.
Results: About 20% of CLL samples in our cohort displayed discordant VLA-4 and CD38 risk, with either high VLA-4 and low
CD38 risk or vice versa. Using particularly such samples, we observed that VLA-4, and not CD38, was responsible for
recirculation of CLL cells to murine BM. Human BM infiltration was also significantly higher in patients with high VLA-4 risk
but not high CD38 risk. However, both molecules acted as independent prognostic markers. While both VLA-4 and CD38
expression were increased in BM-derived CLL cells, and VLA-4+ and CD38+ subpopulations showed enriched Ki-67
expression, VLA-4 did not contribute to CLL cell protection by stromal cells in vitro.
Conclusions: Our data argue for a prominent role of VLA-4 but not CD38 expression in the homing of CLL cells to BM niches
and in human BM infiltration,but only a limited role in their protection by stromal cells.
Citation: Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, et al. (2011) Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic
Lymphocytic Leukemia Cells. PLoS ONE 6(8): e23758. doi:10.1371/journal.pone.0023758
Editor: Kevin D. Bunting, Emory University, United States of America
Received March 2, 2011; Accepted July 24, 2011; Published August 18, 2011
Copyright:  2011 Brachtl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH, SFB program P021 to RG, grants from the
Austrian National Bank (no. 13420 to TNH), the Austrian Science Foundation (FWF no. P19481-B12, L488-B13 to AE, SFB program P021 to RG), and the province of
Salzburg. GB was a recipient of a DOC-FFORTE-fellowship of the Austrian Academy of Sciences. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: t.hartmann@salk.at
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
accumulation of CD5+ B lymphocytes in the blood, bone marrow
(BM) and secondary lymphoid tissues. According to the current
view, CLL cells are highly dependent on microenvironmental
interactions that provide proliferative and prosurvival stimuli to
the malignant cells. CLL is a heterogeneous disease with a highly
variable clinical course and a number of molecular prognostic
markers have been identified to help determine that course.
Among these are VLA-4 and CD38,[1–3] two surface molecules
that are believed not only to be mere markers of disease
aggressiveness but also to play a role in CLL pathogenesis.
VLA-4 (a4b1, CD49d/CD29) is the exclusive member of the a4
integrin subfamily expressed by CLL cells and has recently been
identified as a negative prognostic marker in this disease[2,3].
VLA-4 plays a key role in the retention of hematopoietic
progenitors in BM stroma, which is required for normal early B
cell development.[4] The second prognostic indicator, CD38, is a
promiscuous glycoprotein that functions as an ectoenzyme, a
surface receptor, and an adhesion molecule.[5] In CLL, CD38
ligation in the presence of IL-2 induces the survival and
proliferation of the tumor cells.[6,7] Furthermore, CLL cells
expressing CD38 are thought to have enhanced migratory
capacity.[8,9]
Because VLA-4 and CD38 expression have been described to
be highly associated in CLL,[2,10] we sought to determine their
functional consequences in the context of supportive BM niches.
For this we employed in vivo adoptive transfers of human leukemic
cells into immunodeficient mice, in vitro flow cytometrical
phenotyping of peripheral blood (PB) - and BM-derived CLL
cells, and stromal cell co-culture experiments. Moreover, the
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23758extent of BM infiltration in CLL patients was correlated to the
VLA-4 and CD38 status. Our data suggest that VLA-4 but not
CD38 expression plays a prominent role in the homing of high-risk
CLL cells to supportive BM niches and in human BM infiltration
but only a limited role in supportive CLL cell-stromal cell
interactions in vitro.
Methods
Patient samples
Following written informed consent, samples from 144 CLL
patients seen at the University Hospital Salzburg (Table 1 and
Table S1, Methods S1) were obtained and cytometrically analyzed
for CD38 and VLA-4 (CD49d) expression. Analyzed patients were
chemonaive or had received no chemotherapy in the last six
months. Peripheral blood mononuclear cells (PBMCs) and
mononuclear cells of BM aspirates from CLL patients and
PBMCs from healthy donors were isolated by Ficoll density
gradient centrifugation and freshly used, or viably frozen in FCS
plus 10% DMSO for storage in liquid nitrogen. Thawed cells were
cultured in RPMI medium 1640 supplemented with 10% FCS and
antibiotics prior to use. Bone marrow biopsies from CLL patients
were routinely analyzed by Pathology for CLL infiltration rates.
Mice
NOD/NCrCrl- Prkdc (NOD/SCID) mice were purchased from
Charles River Laboratories, Germany. Experiments were per-
formed under the approval from the Austrian Animal Ethics
Committee. PBMCs (10–25610
6) from CLL patients were
injected into the tail vein of nonirradiated mice. Cell viability
was determined before injection. At indicated time points, animals
were sacrificed, cells were recovered from BM, spleen and other
murine organs, and human cells were detected by flow cytometry
using human-specific antibodies. Cells obtained from mice injected
with PBS only were used to exclude false-positive events. Homing
rates were normalized to the number of analyzed murine cells and
viable injected human cells as described and were comparable to
those of previous reports [11–13]. In addition, absolute recovery
rates of injected human cells in all organs analyzed were calculated
using Flow-Count Fluorospheres (Beckman Coulter, FL).
Immunohistochemistry
Samples from patients (BM) and mice (BM and spleen) were
routinely prepared as 5 mm thick paraffin sections. Basic
histomorphology was evaluated (hematoxylin and eosin staining).
To characterize and quantify the infiltrate of CLL cells,
monoclonal antibodies against CD3, CD5, CD10, CD20, CD23
and CD79 (all from Dako, Glostrup, Denmark) and the
autostainer system (Dako) was used according the manufacturer’s
recommendations. VLA-4 expression was detected by polyclonal
anti-VLA-4 (AHP1225, Serotec, Duesseldorf, Germany) and
CD38 expression by monoclonal anti-CD38 (Eubio). Blind scoring
was carried out in the Department of Pathology.
Ki-67 assessment
For assessment of Ki-67 expression, thawed mononuclear cells
from BM aspirates from CLL patients were stained with CD19-
PC7, CD5-PC5 and CD38-PE (Beckman Coulter) or VLA-4-PE
(or respective isotype control, Becton Dickinson (BD), NJ) before
fixation and permeabilization (Cytofix/Cytoperm, BD). Cells were
then stained with Ki-67-FITC or control-FITC (BD) before flow
cytometrical analysis.
Cell viability
Cells were stained with Annexin V-FITC (Alexis Biochemicals,
Lausen, Switzerland), 7-AAD, anti-CD5-PC7 (Beckman Coulter)
and anti-CD19-PE (BD) and analyzed by flow cytometry. Viable
cells were defined as Annexin V/7-AAD negative. Where
indicated, Flow-Count Fluorospheres were added for calculation
of absolute cells numbers. Samples were analyzed using a FC-500
or Gallios flow cytometer and CXP2.2, Gallios Cytometer
Table 1. Patient characteristics.
VLA-4 Low/
CD38 Low
VLA-4 High/
CD38 High
VLA-4 Low/
CD38 High
VLA-4 High/
CD38 Low Total
N= 83 30 13 18 144
Characteristics Percent of patients (%)
Sex
Female 45 43 31 44 43
Male 55 57 69 56 57
Rai stage
0 4 7 2 34 62 23 9
I-II 48 53 46 56 50
III-IV 5 23 8 22 11
Treatment status
Chemonaive 70 40 54 39 58
Treated 30 60 46 61 42
Risk parameters
IgVH UMT 10 62 70 54 31
FISH High-risk 6 31 27 27 15
ZAP-70 High-risk 21 75 60 40 38
IgVH UMT, unmutated IgVH; FISH High-risk, either del17p, del11q or tri12;
doi:10.1371/journal.pone.0023758.t001
Homing of High-Risk CLL Cells
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Cell culture and Adhesion Assays
For spontaneous apoptosis measurements, freshly isolated
PBMCs (10
6/ml) were cultured in dishes coated with human
serum albumin (HSA, Calbiochem, Merck, Darmstadt, Germany).
For stromal co-culture experiments, M2-10B4 cells (CRL-1972,
ATCC, Manassas, VA) were cultured overnight (300.000 cells per
well, 24-well plate) before PBMCs (10
6/ml) were added. Where
indicated, cells were treated with 5 mM fludarabine (Sigma-
Aldrich, St. Louis, MO). CLL cells were allowed to adhere to
stromal cells for 48 hours before VLA-4 and CD38 expression,
viability and adherence were assessed by flow cytometry. To
determine the percent of adherent cells, the non-adherent fraction
was first separated from the adherent fraction by rigorous washing.
The adherent cells were then harvested by trypinization and
collected in a separate tube. The number of CLL cells in each
fraction was calculated by the use of Flow-Count Fluorospheres.
Where indicated, PBMCs were pretreated with 0.3 mg/ml anti-
VLA-4 antibodies or isotype control (BD) for 30 minutes prior
addition to M2-10B4 cells. To confirm VCAM-1 expression on
M2-10B4 cells, stromal cells were harvested using trypsin/EDTA
and washed with PBS. Cells were stained with anti-VCAM-1-PE
or with respective negative isotype control-PE (both BD) before
flow cytometrical analysis
Ethics
No ethics committee approval is necessary for the experiments
of this study using primary human cells and tissues as it is not part
of any clinical study. This is confirmed by the ethics committee of
Salzburg, Austria (Ref. No. 415-E/1287/8-2011). For experiments
with human cells and tissue samples written informed consent was
obtained from all patients and healthy donors. The patients agreed
that their blood and tissue samples are being used for scientific
purposes and they were informed that those samples are only
obtained when clinically necessary.
All animal (mouse) experiments were performed under the
approval from the Austrian Animal Ethics Committee. The
Federal Ministry for Science and Research of Austria granted
permission (Ref. No. 14606/9-2005) to perform animal experi-
ments in accordance with Animal Experimentation Law (TVG)
(BGBl.Nr.501/1989, last changed to BGBl. I Nr.162/2005).
Statistical analysis
All statistical analyses were performed using Graphpad Prism
(Graphpad Software, La Jolla, CA). All data were tested for
normal distribution. Comparisions of normally distributed data
from two groups were done with t-tests (Paired or Unpaired t-tests,
respectively), while nonparametric data sets were compared using
Wilcoxon signed rank test (paired analysis) or Mann Whitney test
(unpaired analysis). For comparing three or more groups one-way
ANOVA and respective nonparametric tests were used as well as
corresponding post hoc tests. Data are presented as scatter, line, or
columns plots. Differences were considered statistically significant
when P,.05. P-values,.05 are marked with *, ,.01 with ** and
,.001 with ***.
Results
VLA-4 expression is significantly associated with CD38
expression
Prior to functional studies, we analyzed the VLA-4 and CD38
expression on CLL cells from the PB of 144 CLL patients. CLL
samples with VLA-4 expression on $ 30% of the CLL cells were
defined as VLA-4 high-risk samples [2,3]. For definition of CD38
high-risk samples, an equivalent cut-off value of $ 30% was used
as previously described [1]. Using both parameters as categorical
variables, we found a strong association between the VLA-4 and
CD38 risk groups (Chi-square Test, Chi-square = 36.62,
p,.0001), and a positive correlation of the individual expression
levels (Fig. 1). Nevertheless, 31 patients (21.5%) in our cohort
displayed discordant VLA-4 and CD38 expression, with either low
VLA-4 and high CD38 risk (VLA-4-/CD38+, n=18) or vice versa
(VLA-4+/CD38-, n=13).
Expression of VLA-4 but not CD38 defines high BM
homing and human BM infiltration in discordant cases
Havingobserved the phenotypic association ofVLA-4 and CD38
in CLL cells, we investigated the individual as well as the combined
contribution of these molecules to CLL cell dissemination. To this
end we used in vivo short-term adoptive transfer assays of human
CLL cells into immunodeficient mice, which we had previously
established [12] to monitor the capacity of CLL cells to extravasate
into BM and other organs that may provide an important niche for
leukemic cells [14]. PBMCs of CLL patients were injected into the
tail veins of NOD/SCID mice. Mice were sacrificed after the
incubation period, and CLL cells were cytometrically identified in
the murine organs by a combination of human-specific antibodies.
A description of the gating strategy is depicted in Fig. 2A. First, we
evaluated the kinetics of CLL homing using a patient sample with
both high VLA-4 and CD38 expression. CLL cells rapidly left the
blood and homed to BM and spleen within 3 hours (Fig. 2B). In all
organs combined, we detected a total of 39.1% of the originally
injected CLLcellsofthe sample.WefoundmostcellsinBM,spleen,
and liver, little remained in the blood (Fig. 2C). Tiny fractions were
located in the kidneys, lung, heart and lymph nodes (Fig. 2C), while
no CLL cells could be detected in the peritoneal cavity, thymus or
brain (data not shown).
Next, we compared the relative homing rates of different CLL
patient samples after 3 hours with regard to their individual VLA-
4 and CD38 expression. Although these parameters were
associated in most patient samples, a significant proportion of
patients showed a discordant VLA-4 and CD38 risk. In order to
discriminate the roles of VLA-4 and CD38 in BM homing, we
especially investigated the capacity of CLL cells from these
discordant samples to home to BM. CLL cells from VLA-4-/
CD38- patients showed significantly lower BM homing rates than
Figure 1. VLA-4 and CD38 expression are associated in CLL
cells. Percent VLA-4+ correlated to percent CD38+ CLL cells of 144 CLL
patients (Spearman’s Rho = .6293, P,.0001). Red lines depict cut-offs
between low and high-risk samples for each parameter, separating the
cohort into four subgroups. Of note, 31 patients in our cohort (21.5%)
showed discordant VLA-4 and CD38 risk.
doi:10.1371/journal.pone.0023758.g001
Homing of High-Risk CLL Cells
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cells were hardly able to enter BM, while VLA-4+/CD38- samples
displayed high BM homing rates, comparable to VLA-4+/CD38+
samples (Fig. 3A). In contrast, the spleen homing rates did not
significantly differ between these four groups (Fig. 3A).
Of note, CLL cells from patients with combined high VLA-4
and CD38 risk had similar BM and spleen homing rates as healthy
B cells (data not shown). We also verified these results by analyzing
BM and spleen sections from several recipient mice by
immunohistochemisty (Table 2).
For further confirmation, we correlated the individual BM
homing rates with the VLA-4 and CD38 expression levels. The
higher the percentage of VLA-4 positive CLL cells, the more cells
were able to home to the murine BM, while there was no
significant correlation of BM homing and CD38 expression
(Fig. 3B). In addition, pretreatment of human cells with the
blocking anti-VLA-4 antibody, HP2.1, strongly antagonized BM
homing (Fig. S1A), confirming our previous observation using a
different antibody clone, HP1.2 [12]. Importantly, pertussis toxin,
an inhibitor of Gai protein subunit signal transduction which is
usually coupled to chemokine signaling, almost completely
abrogated CLL homing to the BM (Fig. S1B).
Human BM lymphoid infiltration in VLA-4/CD38
discordant cases
Our data suggest that in cases of discordant VLA-4/CD38
expression, only CLL cells with a VLA-4+ phenotype display an
increased recirculation capacity to BM niches. We next wished to
explore whether this characteristic clinically manifests in the extent
of human BM infiltration with leukemic cells. Therefore, we used
bone marrow biopsy histology from CLL patients to determine
their BM lymphoid infiltrate rate. While we did not observe
significant differences in the pattern of BM infiltration (categorized
as diffuse, interstitial or nodular) between VLA-4-/CD38+ and
VLA-4+/CD38- cases, we clearly detected a difference in the
extent of lymphoid infiltrate in BM. As depicted in Fig. 4A,
Figure 2. Homing capacity of CLL cells. (A) Representative plots of human CLL and T cells in a BM sample from a NOD/SCID mouse acquired by
flow cytometry. Total mouse and human lymphocytes were gated in the FS/SS plot. Human cells were identified by anti-human CD45 staining and
were analyzed for their CD19 and CD5 expression. CLL cells were defined as CD19+CD5+ and T cells as CD19-CD5+. (B) Time course experiment.
Percent of injected human CLL cells detected in PB, and BM and spleen homing rates at the indicated time points. The red arrow marks lowest (PB)
and highest (BM and spleen) cell numbers. (C) Percentage of injected CLL cells from a high-risk patient detected in various organs of a NOD/SCID
mouse 180 min after injection. Homing rates were normalized as described [12]: number of human cells analyzed per 10
6 mouse cells (total cells) per
10
6 injected viable human target cells.
doi:10.1371/journal.pone.0023758.g002
Homing of High-Risk CLL Cells
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whereas a lymphoid infiltration greater than 50% (‘‘high’’
infiltration) could only be observed in the VLA-4+/CD38- cases
(Chi-Square Test, p=.025). Notably, patients with VLA-4+/
CD38+ expression as well as patients with discordant VLA-4 and
CD38 expression displayed a significant shorter time to treatment
than patients with VLA-4/CD38 low-risk but there was no
significant difference between high-risk patient groups (combined
or discordant) in terms of treatment-free survival (Fig. 4B).
VLA-4 and CD38 expression is increased in BM compared
to PB
The highly correlated VLA-4 and CD38 expression in CLL and
the association of VLA-4 expression with leukemic BM infiltration
prompted us to investigate whether there are differential
compartment-specific alterations in VLA-4 and CD38 expression.
We therefore analyzed the percentage of CD38+ or VLA-4+ cells
in PB and BM aspirate-derived CLL cells of paired patient samples
by flow cytometry. Both VLA-4 and CD38 expression were
significantly increased in BM aspirates compared to the PB pool
(Fig. 5AB), although this increase was small in most cases. Of note,
remarkably increased VLA-4 expression was found in the BM of
three samples with ‘‘intermediate’’ VLA-4 expression (Fig. 5A). As
BM aspirates generally contain a relevant amount of PB that
considerably dilutes the actual BM, we also performed immuno-
histochemistry on selected BM patient samples (Fig. 5C). In BM
sections of a patient with very low VLA-4 and CD38 expression
(,1.5%) and nodular CLL infiltrations, the VLA-4 negative CLL
clone was clearly visible but was surrounded by high VLA-4
expressing BM areas. In contrast, the CLL clone and the
surrounding BM areas were negative for CD38 in the same
sample. In BM sections of a high-risk patient with diffuse
infiltration, which is associated with accelerated disease[15],
VLA-4 and CD38 expression in the CLL cells infiltrating the
Figure 3. VLA-4, and not CD38, is essential for BM homing. Human CLL cells from different patients were injected into NOD/SCID mice. After
180 min mice were sacrificed and the number of human cells detected by flow cytometry. (A) BM and spleen homing rates of CLL cells from patients
separated into four groups according to their VLA-4 and CD38 risk status (VLA-4-/CD38-, n=9; VLA-4+/CD38+, n=10; VLA-4-/CD38+, n=7; VLA-4+/
CD38-, n=10; Anova, Kruskal-Wallis test, BM: p,.0001, Spleen: p=0.1637, and Dunn’s Multiple Comparison test). (B) Correlation of percent VLA-4+
CLL cells of patients used in homing assays to corresponding BM homing rates (n=36, Linear regression, R
2=.5804, p,.0001) and correlation of
percent CD38+ CLL cells of patients used in homing assays to corresponding BM homing rates (n=36, Linear regression, R
2=.0289, p=.3208).
Homing rates were normalized as described[12]: number of human cells analyzed per 10
6 mouse cells (total cells) per 10
6 injected viable human
target cells. *, P,.05; **, P,.01; ***, P,.001.
doi:10.1371/journal.pone.0023758.g003
Table 2. Detection of human B cells in organs of NOD/SCID
mice via immunohistochemistry.
Human B cells (CD20, CD79a) Bone marrow Spleen
PBS control 22
CLL Low-risk 2 ++
CLL High-risk ++
Healthy control ++
Exemplary analysis. - negative; + only single cells are positive; ++ more than one
cell per high power field.
doi:10.1371/journal.pone.0023758.t002
Homing of High-Risk CLL Cells
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Human bone marrow biopsy histology was used to determine the BM lymphoid infiltrate rate of the individual VLA-4/CD38 discordant patients
(n=15). ‘‘High’’: lymphoid infiltration of human BM greater than 50%, ‘‘Low’’: # 50%. (B) Kaplan-Meier analysis of treatment-free survival of CLL
patients (n=144) separated by their VLA-4 and CD38 risk (VLA-4-/CD38-, orange line, n=83; VLA-4+/CD38+, green line, n=30; VLA-4-/CD38+, blue
line, n=13; VLA-4+/CD38-, red line, n=18; Logrank test for trend compared to VLA-4-CD38- control-group, p=.0004). When comparing the individual
survival curves of all patient groups, all three groups with individual or combined high-risk parameters show significantly shorter treatment free-
survival than patient group with VLA-4-/CD38- (VLA-4+/CD38+, p=.0042; VLA-4-/CD38+,p ,.0001, VLA-4+/CD38-, p=.0026; Logrank (Mantel-Cox)
test, adjusted significance level for multiple comparisions of survival curves by Bonferroni method = 0.0083). There is no significant difference in
treatment-free survival between the three high-risk groups (VLA-4+/CD38+ vs. VLA-4-/CD38+, p=.1861; VLA-4+/CD38+ vs. VLA-4+/CD38-, p=.9346;
VLA-4-/CD38+ vs. VLA-4+/CD38-, p=.2350; Logrank (Mantel-Cox) test, adjusted significance level for multiple comparisions of survival curves by
Bonferroni method = 0.0083).
doi:10.1371/journal.pone.0023758.g004
Figure 5. VLA-4 and CD38 are higher expressed in BM than in PB. Paired analysis of VLA-4 (A) and CD38 expression (B) on CD19+CD5+ CLL
cells in PB and BM samples of patients by flow cytometry (n=16, Wilcoxon signed rank test, VLA-4: p=.0069, CD38: p=.0362). Cases marked with red
boxes in the left panels are drawn on a smaller scale in the right panels. (C) Immunohistochemical analysis of VLA-4 and CD38 expression in BM
sections of a low-risk (VLA-4-/CD38-) CLL patient (top), and of a high-risk (VLA-4+/CD38+) patient (bottom) shown with indicated magnitudes.
*, P,.05; **, P,.01.
doi:10.1371/journal.pone.0023758.g005
Homing of High-Risk CLL Cells
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was uniformly highly expressed, whereas CD38 expression was
more diverse, i.e. in some areas CLL cells expressed high levels of
CD38, whereas in other areas CD38 expression was largely
negative.
VLA-4 negative and CD38 positive subpopulations in BM
show enriched Ki-67 expression
Since we found that both VLA-4 and CD38 were elevated in
the BM, we also analyzed expression of the proliferation marker
Ki-67 in CLL cells of BM aspirates by flow cytometry. Following
Figure 6. Ki-67 expression in BM aspirates is higher in CLL samples from high-risk patients, and VLA-4 negative and CD38 positive
subclones express higher levels of Ki-67 in BM. MNCs from BM aspirates of CLL patients were stained with anti-CD19-PC7, CD5-PC5 and either
VLA-4-PE or CD38-PE or respective isotype control-PE antibody and intracellulary stained with Ki-67-FITC or isotype control before flow cytometric
analysis. (A) Left. Difference in Ki-67 expression in CLL samples from VLA-4 low (n=6) and high-risk (n=6, Unpaired t-test, p=.0298) patients as well
as CD38 low (n=5) and high-risk patients (n=7, Unpaired t-test, p=.0278). Right. Difference in Ki-67 expression in CLL cells from patients with a
combined low risk (-/-, VLA-4-/CD38-, n=4), with discordant VLA-4 and CD38 risk (+/22 /+, n=3), and VLA-4+/CD38+ (+/+, n=5, ANOVA, One-way
analysis of variance, p=.0233, Bonferroni’s multiple comparision test). (B) Representative plot of CLL cells (CD19+/CD5+) analysed for their VLA-4
expression. VLA-4 negative and VLA-4 positive CLL cells were gated and further analyzed for their Ki-67 expression. (C) Representative plots for CD38
analysis. Percentage of Ki-67+ CLL cells in (A, right) VLA-4 negative and VLA-4 positive subclones within individual patients (n=12, Paired t-test,
p=.0275) or in (B, right) CD38 negative and CD38 positive subclones (n=12, Paired t-test, p=.0048). neg, negative subclones; pos, positive
subclones. *, P,.05; **, P,.01.
doi:10.1371/journal.pone.0023758.g006
Homing of High-Risk CLL Cells
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expression dependent on the risk status and its expression within
CLL clones of the individual samples. We first compared the %
Ki-67+ CLL cells between the groups and found that Ki-67
expression in CLL cells (identified by their CD5, CD19 expression)
was significantly higher in the VLA-4+CD38+ group than in the
VLA-4-CD38- group (median Ki-67 expression 4.72% vs 0.65%)
(Fig. 6A). Three patients with discordant VLA-4 and CD38 risk
displayed intermediate Ki-67 expression (Fig. 6A).
Next, we determined Ki-67 expression in the VLA-4 negative
and VLA-4 positive or CD38 negative and CD38 positive
subfractions of individual CLL samples in BM aspirates by flow
cytometry. The gating strategy, according to [16], is depicted in
Fig. 6B, C. In the BM, Ki-67+ CLL cells were significantly
enriched in VLA-4 positive (Fig. 6B), as well as in the CD38
positive, CLL subclones (Fig. 6C). While VLA-4 negative
subclones had more diverse Ki-67 expression, CD38 negative
subclones were nearly uniformly negative for Ki-67.
High-risk CLL cells display higher spontaneous apoptosis
rates in vitro
Our data suggest that expression of VLA-4 may allow
circulating CLL cells to enter BM where they are likely to
encounter anti-apoptotic and/or proliferative stimuli through
interactions with accessory cells, thereby explaining the more
aggressive clinical course of VLA-4+ patients. In this respect, co-
culture with BM stromal cells has been shown to rescue CLL cells
from otherwise rapid spontaneous apoptosis in vitro [17].
Consequently we were interested in the extent of stroma-derived
survival benefits for the distinct risk groups. Therefore, we first
compared the in vitro apoptosis rates of CLL cells from these risk
groups. We observed no difference in the basal viability of CLL
cells between high-risk and low-risk patients immediately following
PBMC isolation (data not shown). However, after 48 hours in
culture, the spontaneous apoptosis rates of CLL cells from high-
risk patients were significantly higher than those of low-risk
patients (Fig. 7). This was true for the VLA-4 (Fig. 7A) as well as
CD38 high-risk groups (Fig. 7B). Cells from three patients with
discordant VLA-4 and CD38 risk were tested and their
spontaneous apoptosis rates were intermediate (Fig. 7C).
Adhesion of CLL cells to stromal cells via VLA-4 confers
only limited survival supports
Next, we compared the protective effects of stromal cells on
CLL cells from low- and high-risk patients. We cultured CLL cells
together with the murine BM-derived cell line M2-10B4, a
commonly used model system for tumor cell-marrow interactions
[17], Expression of the VLA-4 ligand, VCAM-1, on the surface of
M2-10B4 cells was confirmed by flow cytometry (Fig. 8A). We first
wanted to investigate the influence of co-culture on the expression
of VLA-4 and CD38, and the viability of CLL cells. In vitro
culture of CLL cells alone for up to 48 hrs resulted in a slight but
non-significant decrease in VLA-4 expression of the CLL cells
(Fig. 8B). The additional presence of M2-10B4 cells did not
significantly alter the VLA-4 expression. Likewise, CD38 expres-
sion was neither influenced by the culture time nor the presence of
stromal cells (Fig. 8B). Next, we found that CLL cells from low-
and high-risk groups were equally protected by stromal cells from
spontaneous or fludarabine-induced apoptosis after 48 hours
(VLA-4: Fig. 8C, CD38: data not shown). This implies, however,
that the net effect of stromal cell protection was much greater in
high-risk CLL cells, since high-risk CLL cells were significantly less
viable than low-risk cells when cultured without stromal support
(Fig. 7).
We found significantly increased adhesion of CLL cells from
VLA-4 high-risk patients to M2-10B4 cells as compared to cells
from low-risk patients (Fig. 8Da). The same was true for CD38 risk
groups, but the difference was only borderline significant
(p=0.056, Fig. 8Db). The increased adhesion of CLL cells from
VLA-4 high-risk patients was blocked when anti-VLA-4 antibodies
were added, while adhesion levels of low-risk samples were
unaffected (Fig. 8E). When we assayed the non-adherent and
adherent fractions separately for cell viability, we found that CLL
cells in both fractions where similarly protected by stromal cells
against spontaneous and fludarabine-induced apoptosis (Fig. 8F
and data not shown). Furthermore, the addition of VLA-4
blocking antibodies had no effect on CLL cell viability in the co-
culture setting. Thus, VLA-4-mediated adhesion did not directly
impact viability.
Collectively, our data suggest a prominent role of VLA-4, but
not CD38, in the migration of CLL cells to supportive BM niches.
However, VLA-4 mediated adhesion to BM stromal cells is not a
dominant factor in protecting CLL cells from apoptosis in vitro.
Discussion
Emerging evidence suggests that the proliferation and survival
of CLL cells is dependent on their interplay with accessory cells
and molecular factors in supportive niches.[18] It is therefore
essential to define the molecular mechanisms underlying the
trafficking of CLL cells into these niches. Among the plenitude of
Figure 7. VLA-4 and CD38 high-risk CLL samples show higher
spontaneous apoptosis rates. PBMCs from different CLL patients
were cultured in vitro for 48 hours. Viability of CLL cells was analyzed by
flow cytometry after 48 hours. Difference in viability of samples from (A)
VLA-4 low (n=18) and high-risk (n=10; Unpaired t-test, p=.0004)
patients and (B) and of CD38 low (n=19) and high-risk (n=9; Unpaired
t-test, p=.0005) patient samples. (C) Difference in viabilty after 48 hours
of cells from patients with a combined low risk (2/2, VLA-4-/CD38-,
n=17), with discordant VLA-4 and CD38 risk (+/22/+, n=3), and with
combined high risk (+/+,V L A - 4 +/CD38+, n=8, ANOVA, One-way
analysis of variance, p=.0007, Bonferroni’s multiple comparison test).
***, P,.001.
doi:10.1371/journal.pone.0023758.g007
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influence, VLA-4 and CD38 may be key players regulating tissue
invasion and infiltration in CLL [19]. Since the majority of CLL
samples show associated VLA-4 and CD38 expression, their
individual roles in CLL cell migration and interactions with
supportive accessory cells are still unclear. Therefore, in this study,
we particularly analyzed samples with discordant VLA-4/CD38
expression. Collectively, our data argue for a higher propensity of
high-risk CLL cells to infiltrate supportive BM niches as a result of
their VLA-4 rather than CD38 expression, but only a limited role
of VLA-4 in malignant cell-stroma interactions.
VLA-4 is a central player in B lymphopoiesis and is highly
expressed in normal PB and BM B lymphocytes.[20] Thus, the
variable VLA-4 expression and its applicability as a prognostic
marker in CLL is quite a unique feature among B cell
malignancies. In line with recent studies noting a high correlation
between VLA-4 and CD38 expression,[2,3] we detected not only a
strong association between the risk groups but also a positive
Figure 8. CLL cells from patients with different risk-groups are equally protected by stromal cells but cells from high-risk patients
are able to adhere in higher numbers. (A) VCAM-1 expression on M2-10B4 cells was detected by flow cytometry. (B) PBMCs from CLL patients
were cultured in the absence or presence of M2-10B4 cells for 48 hours. VLA-4 and CD38 expression levels on viable CD19+CD5+ CLL cells were
determined by flow cytometry at indicated time points. (n=5, Repeated Measures ANOVA, VLA-4, p=.0083; CD38, p=.1681; Bonferroni’s Multiple
Comparision Test) (C-F) PBMCs from CLL patients were co-cultured with M2-10B4 cells and after 48 hours viability and adhesion of CLL cells was
determined by flow cytometry. (C) Viability of CLL cells from patients with low (n=7) and high (n=7) VLA-4-risk left untreated (Mann Whitney test,
p=.9015) or treated with 5 mM fludarabine (Unpaired t-test, p=.4626). (D) Adhesion of CLL cells to M2-10B4 of different patient risk-groups (a, VLA-4,
low, n=7; high, n=7; Unpaired t-test, p=.0003; b, CD38, low, n=9; high, n=5, Unpaired t-test, p=.0560). (E) Adhesion of CLL cells to M2-10B4 cells
of VLA-4 low-risk (n=7) or high-risk (n=7) patient samples pretreated with isotype control (Control) or anti-VLA-4 antibodies. (Paired t-test, low-risk:
p=,4876; high-risk: p=.0059) (F) Viability of non-adherent and adherent CLL cells to M2-10B4 cells of VLA-4 low-risk (n=7, Paired t test, p=.1186) or
high-risk (n=7, Wilcoxon signed rank test, p=.5781) patient samples. **, P,.01, ***, P,.001.
doi:10.1371/journal.pone.0023758.g008
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in about 20% of the cases we observed discordant VLA-4 and
CD38 expression, and we specifically used these cases to explore
the individual roles of these two molecules. We found that VLA-4
expression on its own was sufficient to allow entry into the BM,
while CD38 expression was dispensable (Fig. 3A). In fact, the BM
homing rate could directly be correlated with the extent of VLA-4
(Fig. 3B) but not CD38 expression and was completely abrogated
by anti-VLA-4 antibodies and the Gai inhibitor pertussis toxin
(Fig. S1), suggesting that functional VLA-4 and Gai-dependent
chemokine signaling is needed for crossing the BM vasculature.
The significant correlation between the extent of VLA-4 positivity
of the sample and the BM homing capacity of the cells is in line
with our previous observation of reduced circulation capacity of
CLL cells at early Rai stages, which displayed lower VLA-4
expression than normal B lymphocytes.[12] More importantly,
clinically, the VLA-4 state is directly manifested in the extent of
human BM infiltration while the CD38 state did not influence it
(Fig. 4A). Still, it is important to note that each prognostic marker
on its own, VLA-4 or CD38, was sufficient to predict shortened
time to treatment of the patients (Fig. 4B).
The exact role of CD38 in CLL pathophysiology remains an
open question. In our setting, BM homing was not specifically
blocked using anti-CD38 antibodies (OKT10, data not shown),
which were previously shown to antagonize cell adhesion to
hyaluronic acid and BM endothelium.[21] Yet, in a recent study,
the homing of CLL samples to the BM could be abrogated with a
high dose of a different anti-CD38 clone.[9] However, the authors
did not analyze whether CD38 expression is needed for entry into
the BM.[9] CD38 is a cyclic ADP-ribose that influences calcium
signaling[6] and has the propensity to laterally associate with
several molecules in membranal lipid rafts [22]. Our data clearly
support the reported correlation between CD38 and proliferation
[16,23], which we observed to be stronger than that of VLA-4 and
proliferation (Fig. 6). We therefore speculate that CD38 is
primarily involved in calcium signaling during proliferation.
Although CD38 may additionally act as an adaptor molecule that
fine-tunes calcium signaling during chemokine-induced migratory
responses [6], integrin-dependent signaling routes seem to be
dominant and able to fully overrule its contribution.
Occasional in vitro chemoresistance of VLA-4 positive samples
was observed in an earlier study [24]. In light of this study of de la
Fuenta, our finding that VLA-4 high risk CLL cells are
particularly sensitive to the absence of prosurvival stimuli from
accessory cells (Fig. 7) was unexpected. However, our results are in
complete consistency with the recent report by Coscia and
colleagues who observed that high-risk CLL cells with an
unmutated IGHV status were extremely vulnerable when
removed from microenvironmental protection [25]. These differ-
ences between the risk groups might be based on alterations in
microenvironment-induced NFkB signaling cascades [25]. Thus,
disrupting microenvironmental interactions, potentially in combi-
nation with NFkB targeting, bears particular therapeutic potential
for patients with a negative molecular prognostic signature.
Despite higher adhesion rates of VLA-4 positive CLL cells to
stromal cells, a VLA-4 dependent adhesion-mediated survival
support could not be confirmed in our study (Fig. 8). Our results
suggest a more complex scenario where CLL cells use VLA-4 for
localization in protective niches rather than as a direct prosurvival
molecule. This clearly does not reduce the therapeutic potential of
VLA-4 antagonism, but rather suggests that the predominant
effect of this interference will be reduction of malignant cell
localization in protective microenvironmental niches such as bone
marrow. We do also not exclude that VLA-4 mediated cell-cell
contact may be a means to prime the stromal cells to secrete
specific survival factors. VLA-4 low expressing cells appear to be
less dependent on these cell-cell interactions and survival cascades.
In summary, our data suggest that VLA-4, rather than CD38, is
mainly responsible for the recirculation of high-risk CLL cells into
BM and for high BM infiltration observed in CLL patients. VLA-4
seems to be necessary to position those cells that are highly
dependent on accessory survival signals at the appropriate
supportive niche. Consequently, drugs that interfere with the
homing properties of these cells, e.g., the anti-VLA-4 antibody
Natalizumab[26], may be of particular benefit for this high-risk
patient subgroup, especially in combination with current cytotoxic
therapies. Moreover, Natalizumab could be used to target residual
CLL cells surviving in the BM after conventional treatments[27],
forcing them back into the blood stream where they become more
vulnerable to treatment.
Supporting Information
Figure S1 (A) BM homing rates of CLL cells from high-risk
(VLA-4+/CD38+) patients (n=3) that were either untreated or
pretreated with anti-VLA-4 antibodies before injection into mice
(Paired t-test, p=.0212). (B) BM homing rates of tumor cells from
three high-risk (VLA-4+/CD38+) CLL patients that were either
untreated or incubated with pertussis toxin (PTX) overnight before
injection into mice (Paired t-test, p=.0227). Homing rates were
normalized as described[12]: number of human cells analyzed per
10
6 mouse cells (total cells) per 10
6 injected viable human target
cells. *, P,.05.
(TIF)
Table S1 Detailed patient characteristics.
(DOCX)
Methods S1
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